- Home
- STTK vs HRTX Comparison
STTK vs HRTX Comparison
Compare STTK & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STTK | HRTX |
|---|---|---|
| Founded | 2016 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 265.9M |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | STTK | HRTX |
|---|---|---|
| Price | $6.18 | $0.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $7.60 | $4.50 |
| AVG Volume (30 Days) | 617.5K | ★ 2.0M |
| Earning Date | 03-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,000,000.00 | ★ $154,904,000.00 |
| Revenue This Year | N/A | $15.28 |
| Revenue Next Year | N/A | $20.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.36 |
| 52 Week Low | $0.69 | $0.80 |
| 52 Week High | $6.27 | $2.61 |
Technical Indicators
Market Signals| Indicator | STTK | HRTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.59 | 21.83 |
| Support Level | $1.85 | N/A |
| Resistance Level | N/A | $1.41 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 93.80 | 0.65 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.